DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Grey A, Bolland M, Gamble G et al.
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
J Clin Endocrinol Metab 2007;
92 (04) 1305-1310
http://www.ncbi.nlm.nih.gov/pubmed/17264176
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.